Genmab

	22/9 06:21 af transalp	Go morgen.. :)
	22/9 06:10 af Helge Larsen/PI-redaktør	God morgen. :-)
	21/9 23:51 af Sukkeralf	(link)
	21/9 19:18 af peter12	On the latest fireside session JvdW said that Europe would require larger trials for TV
	21/9 19:11 af GeorgeBest	Yes, Japan is very important, they don‘t give their teenage girls the hpv vaccine
	21/9 19:08 af Solsen	Many i Japan...
	21/9 18:49 af E L	maybe it was in the annual report
	21/9 18:48 af E L	the real drama is offcourse in developing countries. a few hundred thousand....
	21/9 18:47 af E L	and Europe is a multiple of that, i think 3 or 4 times as much. we had an article here about it , but can't remember where
	21/9 18:27 af Solsen	(link) Annonce på Twitter siger 13.800+ nye cervical patienter i US årligt. Så stort marked og de har vel også åbnet for at tiso kunne blive blockbuster. Vi har vel heller ikke set weekly behandling, som forventes med bedre resultat.
	21/9 17:19 af GeorgeBest	.@rcoledude presents results from the InnovaTV trial of tisotumab vedotin. There was a 24% response rate in patients w/ recurrent #cervical cancer, >50% of patients had stable disease beyond 6 months! (link)
	21/9 17:18 af bikube	Det eneste jeg har, der ikke er rødt i dag er mine Bear Tesla.
	21/9 17:14 af Bulder	Det her er kun begyndelsen på tiso. Der er større forventninger til andre kræftformer. F,eks, bugspytkirtlen, hvor præklinikken så god ud. Desuden vil der komme kombinationsbehandlinger.
	21/9 17:14 af Helge Larsen/PI-redaktør	Novo også drønstærk i dag.
	21/9 17:04 af Mcjean	Yep! Tak til Genmab for at give folk håb.
	21/9 17:01 af Solsen	Imponerende ganske enkelt !
	21/9 17:00 af GeorgeBest	-0,16% er til at holde til på en dag hvor DAX futter er neden med 4,5%
	21/9 16:53 af Don Joning	Det giver jo alt sammen til at lave en robust forretning, med mange ben at stå på og det er jo ikke det nemmeste i verden de udvikler på - det kunne også have været et hard stop uden signifikant effekt og 0 værdi i det område.
	21/9 16:50 af E L	fiercebiotech - ESMO: Seattle Genetics' ADC candidate curbs hard-to-treat cervical cancer - (link)
	21/9 16:47 af GeorgeBest	men tiso kan måske også bruges i andre cancer former. der skulle også komme data på det i år
	21/9 16:46 af GeorgeBest	jo
	21/9 16:46 af Don Joning	ja, men er det ikke 50/50
	21/9 16:46 af GeorgeBest	skal også deles med SGEN
	21/9 16:45 af Don Joning	tak GB det er da alligevel også lidt...

	21/9 16:45 af GeorgeBest	årligt topsalg
	21/9 16:45 af GeorgeBest	Tiso: jeg har set estimater på et topsalg på 750M USD i cervical cancer
	21/9 16:44 af GeorgeBest	knock your socks off data er mere relateret til epcoritamab og PD-L1x4-1BB
	21/9 16:44 af Don Joning	nogen der har nogen bud på hvor værdifuldt tiso i cervical cancer kan blive?
	21/9 16:43 af bikube	Det er da det man forstår ved "late breaking".
	21/9 16:43 af GeorgeBest	der var ikke forventet mere for tiso
	21/9 16:41 af Macabo	ORR 24% og DOR 8,3 måneder - det er godt men ikke knock of socks niveau
	21/9 16:35 af GeorgeBest	thanks E L
	21/9 16:34 af E L	correction for the link GB (link)
	21/9 16:31 af GeorgeBest	The results of the tisotumab vedotin phase 2 clinical trial are encouraging as they demonstrate clinically meaningful, durable responses with a manageable side effect profile
	21/9 16:29 af GeorgeBest	(link)
	21/9 16:28 af GeorgeBest	Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
	21/9 14:55 af E L	(link) Amgen showing bispecific CD3x PSMA , like JNJ-63898081
	21/9 11:14 af Bulder	Could be RA. Has been discussed before. I think Janssen has an unused IND for dara in RA. (link)
	21/9 10:19 af E L	ok. we know Mayo has a Dara trial in CLL, in combination with Ibrutinib, will be interesting to see
	21/9 09:55 af Darvin	EL It was Rajkumar who announced It yesterday. And - depending on how you read the text - I read it as if they will open a trial for various autoimmune diseases - but only my way to read it
	21/9 09:50 af Darvin	Tillykke og godt gået Helge :-D
	21/9 09:45 af Helge Larsen/PI-redaktør	:-)
	21/9 09:45 af Sukkeralf	ATH
	21/9 09:33 af Helge Larsen/PI-redaktør	Styrken er i top: (link)
	21/9 09:26 af Helge Larsen/PI-redaktør	Tak transalp og Pensionist:-)
	21/9 09:21 af Helge Larsen/PI-redaktør	"The treatment beat back cancer in 20 newly diagnosed, never-before-treated patients, shrinking tumors in all of them. And in 45 patients whose disease had worsened despite taking Tagrisso, J&J’s treatment curbed tumor growth in 60% of them and shrank tumors in 36% of them. One patient had a complete response, meaning the drug eliminated all signs of cancer".
	21/9 08:54 af E L	ESMO: Janssen’s anti-EGFR combo tackles lung cancer ahead of phase 3 Tagrisso showdown (link)
	21/9 08:35 af E L	@Darvin for Mayo to start a trial is definately news. Really curious if it will be only for Lupus or also for other autoimmune diseases? The NEJM article attracted a surprisingly large number of positive comments from MDs on twitter over the last few days.
	21/9 08:27 af E L	and since nobody bothered to correct my comment from yesterday evening (even thought i am sure you had all seen the mistake) ; i meant 2 Ph III trials for Amivantamab
	21/9 08:24 af E L	2 more twitter threads on Amivantamab, Stephen V Liu (link) and Joshua Bauml (link)